Opinion statement
Myoclonus is a hyperkinetic movement disorder characterized by quick, involuntary jerks. It encompasses a vast range of etiologies and widespread anatomic locations. Treatment frequently requires multiple agents and is often only partially beneficial. These patients pose a considerable challenge for the clinician, further complicated by the fact that many of the treatment choices lack evidence-based support. In the past few years, publications regarding therapy have been largely observational case reports or series. Although the literature on treatment of cortical myoclonus appears to be growing, evidence regarding myoclonus of noncortical origin is less well established. Investigation of more satisfactory treatments is needed, as this condition can be disturbing, debilitating, and sometimes harmful for patients. Continuing investigations are using various animal models (mostly of posthypoxic myoclonus), electrophysiologic studies, new imaging techniques such as diffusion tensor imaging, and genetic studies. Meanwhile, the clinical approach to diagnosing and classifying myoclonus remains largely unchanged. This review updates readers on current investigations and suggests guidelines for diagnosing and treating myoclonus.
Similar content being viewed by others
References and Recommended Reading
Marsden CD, Hallett M, Fahn S: The nosology and pathophysiology of myoclonus. In Movement Disorders. Edited by Marsden CD, Fahn S. London: Butterworth; 1982:196–248.
Fahn S: Definition and classification of myoclonus. In Advances in Neurology. Edited by Fahn S. New York: Raven Press; 1986:1–5.
Deuschl G, Toro C, Valls-Solé J, et al.: Symptomatic and essential palatal tremor. 1. Clinical, physiological, and MRI analysis. Brain 1994, 117:775–788.
Brown P, Thompson PD, Rothwell JC, et al.: Axial myoclonus of propriospinal origin. Brain 1991, 114:197–214.
Grinker RR, Serota H, Stein SI: Myoclonic epilepsy. Arch Neurol Psychiatry 1938, 40:968–980.
Shibasaki H, Hallett M: Electrophysiological studies of myoclonus. Muscle Nerve 2005, 31:157–174.
Lefaucheur JP: Myoclonus and transcranial magnetic stimulation [review]. Neurophysiol Clin 2006, 36:293–297.
Roze E, Apartis E, Vidailhet M, et al.: Propriospinal myoclonus: utility of magnetic resonance diffusion tensor imaging and fiber tracking. Mov Disord 2007, 22:1506–1509.
Tai KK, Bhidayasiri R, Truong DD: Post-hypoxic animal model of myoclonus. Parkinsonism Relat Disord 2007, 13:377–381.
Van Woert MH, Rosenbaum D: L-5-hydroxytryptophan therapy in myoclonus. Adv Neurol 1979, 26:107–115.
Thal LJ, Sharpless NS, Wolfson L, et al.: Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol 1980, 7:570–576.
Tai KK, Truong DD: Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm 2007, 114:1547–1551.
Pranzatelli MR, Nadi NS: Mechanism of action of antiepileptic and antimyoclonic drugs. Adv Neurol 1995, 67:329–360.
Obeso JA: Therapy of myoclonus. Clin Neurosci 1995, 3:253–257.
Striano P, Manganelli F, Boccella P: Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005, 20:1610–1655.
Frucht S, Louis E, Chuang C, et al.: A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001, 57:1112–1114.
Magaudda A, Gelisse P, Genton P: Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004, 45:678–681.
Papacostas S, Kkolou E, Papathanasiou E: Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci 2007, 29:164–166.
Koskiniemi M, Van Vleymen B, Hakamies L, et al.: Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the safety and efficacy of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998, 64:344–348.
Brown P, Steiger MJ, Thompson PD, et al.: Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993, 8:63–68.
Ikeda A, Shibasaki H, Tashiro K, et al.: Clinical trial of piracetam in patients with myoclonus: nationwide multi-institutional study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord 1996, 11:691–700.
Fahn, S: Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. In Advances in Neurology. Edited by Fahn S. New York: Raven Press, 1979:49–84.
Frucht S: The clinical spectrum of posthypoxic myoclonus. Mov Disord 2000, 15(Suppl 1):2–7.
Frucht S, Bordelon Y, Houghton WH: Marked amelioration of alcohol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem). Mov Disord 2005, 20:745–751.
Jankovic J, Pardo R: Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986, 43:1025–1031.
Siniscali A, Mancuso F, Russo E, et al.: Spinal myoclonus responsive to topiramate. Mov Disord 2004, 19:1380–1381.
Abraham A, Cogan E, Melamed E, et al.: Successful treatment of truncal myoclonus. Mov Disord 2007, 22:1055–1056.
Krause E, Leunig A, Klopstock T, Gürkov R: Treatment of essential palatal myoclonus in a 10-year-old girl with botulinum neurotoxin. Otol Neurotol 2006, 27:672–675.
Penney SE, Bruce IA, Saeed SR: Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006, 253:857–860.
Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management [review]. Neurophysiol Clin 2006, 36:337–343.
Gelisse P, Crespel A, Genton P, Baldy-Moulinier M: Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003, 107:302–303.
Oguni H, Uehara T, Tanaka T, et al.: Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. Neuropediatrics 1998, 29:29–34.
Pueschel SM, Friedman JH, Shetty T: Myoclonic dystonia. Childs Nerv Syst 1992, 8:61–66.
Misbahuddin A, Placzek M, Lennox G, et al.: Myoclonusdystonia syndrome with severe depression is caused by an exon-skipping mutation in the ε-sarcoglycan gene. Mov Disord 2007, 22:1173–1175.
Nygaard TG, Raymond D, Chen C, et al.: Localization of a gene for myoclonus-dystonia to chromosome 7q21–q31. Ann Neurol 1999, 46:794–798.
Frucht SJ, Boredlon Y, Houghton WH, et al.: Pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005, 20:1330–1337.
Cif L, Valente EM, Hemm S, et al.: Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord 2004, 19:724–727.
Magariños-Ascone CM, Regidor I, Martinez-Castrillo JC, et al.: Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005, 76:989–991.
Trottenberg T, Meissner W, Kabus C, et al.: Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001, 16:769–771.
Physicians’ Desk Reference, edn 62. Montvale, NJ: Thomson PDR; 2008.
Drug Topics Red Book, edn 111. Montvale, NJ: Medical Economics; 2007.
Mondria R, de Gier HHW, Boon AJW: New device to control combined lingual and palatal myoclonus. Mov Disord 2007, 22:573–575.
Caviness J, Brown P: Myoclonus: current concepts and recent advances. Lancet Neurol 2004, 3:598–607.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chang, V.C., Frucht, S.J. Myoclonus. Curr Treat Options Neurol 10, 222–229 (2008). https://doi.org/10.1007/s11940-008-0024-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-008-0024-y